Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| B Group, Inc. | 3.28M | $9.0M | 3.27% | -- | 2026-06-30 |
| Long Focus Capital Management, LLC | 2.74M | $8.0M | 2.73% | -2.2K | 2026-06-30 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.64M | $7.0M | 2.64% | -533.7K | 2026-06-30 |
| Nomura Asset Management International Inc. | 226.9K | -- | 0.23% | -- | 2026-06-30 |
| BlackRock, Inc. | 225.4K | -- | 0.22% | -116.1K | 2026-06-30 |
| Morgan Stanley | 85.5K | -- | 0.09% | -1.3K | 2026-06-30 |
| LPL Financial LLC | 84.4K | -- | 0.08% | +70 | 2026-06-30 |
| BNP Paribas Financial Markets | 40.1K | -- | 0.04% | -900 | 2026-06-30 |
| UBS Group AG | 33.9K | -- | 0.03% | +4.2K | 2026-06-30 |
| Rhumbline Advisers | 14.3K | -- | 0.01% | -757 | 2026-06-30 |
